Literature DB >> 24554168

Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome.

Sara Martinelli1, Gian Matteo Rigolin, Genesio Leo, Roberta Gafà, Enrico Lista, Francesca Cibien, Olga Sofritti, Giulia Daghia, Francesco Cavazzini, Antonio Cuneo.   

Abstract

Sweet's syndrome is a rare condition with potentially disabling implications, characterized by painful skin lesions due to neutrophilic dermal infiltration and systemic inflammatory symptoms. A significant proportion of cases is malignancy associated. Hematologic neoplasms, particularly acute myeloid leukemia and myelodysplastic syndromes, are the most commonly associated malignant conditions. Here, we describe the first case of clinical remission of refractory Sweet's syndrome following hypomethylating therapy with azacytidine in a patient with myelodysplastic syndrome who concurrently obtained a complete hematologic response.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24554168     DOI: 10.1007/s12185-014-1527-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

Review 1.  Myelodysplastic syndrome and associated skin lesions: a review of the literature.

Authors:  I Avivi; H Rosenbaum; Y Levy; J Rowe
Journal:  Leuk Res       Date:  1999-04       Impact factor: 3.156

2.  Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.

Authors:  Cristina Alencar; Matthew Abramowtiz; Samir Parekh; Ira Braunshweig; Mark Jacobson; Lewis Silverman; Amit Verma
Journal:  Am J Hematol       Date:  2009-10       Impact factor: 10.047

3.  Azacitidine: a new medication associated with Sweet syndrome.

Authors:  Suzanne Tintle; Vishal Patel; Andrea Ruskin; Charles Halasz
Journal:  J Am Acad Dermatol       Date:  2011-05       Impact factor: 11.527

Review 4.  5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

Authors:  Rena Buckstein; Karen Yee; Richard A Wells
Journal:  Cancer Treat Rev       Date:  2010-06-29       Impact factor: 12.111

5.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

6.  Azacitidine-associated Sweet's syndrome.

Authors:  Hannah B Trickett; Aaron Cumpston; Michael Craig
Journal:  Am J Health Syst Pharm       Date:  2012-05-15       Impact factor: 2.637

7.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

8.  Clonality in the setting of Sweet's syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease.

Authors:  Cynthia M Magro; Bahram Kiani; Jingwei Li; A Neil Crowson
Journal:  J Cutan Pathol       Date:  2007-07       Impact factor: 1.587

Review 9.  Acute febrile neutrophilic dermatosis (Sweet's syndrome).

Authors:  Charles L Anzalone; Philip R Cohen
Journal:  Curr Opin Hematol       Date:  2013-01       Impact factor: 3.284

Review 10.  EPONYM. Sweet syndrome.

Authors:  Mi Jin Kim; Yon Ho Choe
Journal:  Eur J Pediatr       Date:  2010-05-06       Impact factor: 3.860

View more
  1 in total

Review 1.  Sweet's syndrome associated with clonal hematopoiesis of indeterminate potential responsive to 5-azacitidine.

Authors:  George Yaghmour; Eric Wiedower; Bassam Yaghmour; Sara Nunnery; Eric Duncavage; Mike G Martin
Journal:  Ther Adv Hematol       Date:  2016-11-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.